Waseem Qasim, a researcher at the University of London's Great Ormond Street Children's Health Institute (UCL), published an article in Science Translational Medicine, citing two infants with advanced acute lymphoblastic leukemia (ALL). After receiving CAR-T cell therapy, complete recovery was achieved. Both infants treated had relapsed, refractory CD19+ B cell acute lymphoblastic leukemia. The previous treatment was to extract the patient's own immune cells for genetic recombination. The autologous T cell engineering CAR19-T technology has demonstrated significant efficacy in the treatment of leukemia in early clinical trials, but this technique must extract the patient's own cells, making it difficult to achieve mass production. It is generally believed that the practical value of this technique is relatively low for infants and critically ill patients. Kassim’s medical team used a different approach when treating two babies. They successfully produced the "universal" CAR-T cell, UCART19, using the TALEN genetic engineering platform. The team transduce non-human leukocytes with lentiviruses to create antibodies that match donor cells, reducing the likelihood of antibody mismatches. During the genetic engineering process, they simultaneously transduced the T cell receptor alpha chain (edited by the TALEN gene) and the CD52 cell locus through a catalytically active nuclease. In other words, Kassim's team completed the two processes of “injecting CAR†and “disturbing TCR and CD52 in T cellsâ€, so that even if the receptors do not match, CAR-T has the ability to evade rejection from the immune system. . When the universal CAR-T cells were ready, when these ready-made CAR-T cells were injected into the blood of two infants became the key to the trial. The trial team injected only one dose of UCART19 cells after the infant received lymphocyte clearance chemotherapy and anti-CD52 serum therapy. After 28 days, both infants achieved molecular remission, and UCART19 cells survived until the transformation of allogeneic stem cells. Universal CAR-T cells not only show good therapeutic effects on ALL, but also become a bridge for allogeneic stem cell transformation. Both trials were successful and both infants were fully recovered. “After 28 days of treatment, both infants have Molecular remissions,†says Kassim. “Our treatment strategy demonstrates the infinite medical potential of genetic engineering technology.†Kassim’s Therapeutic methods are more practical than traditional allogeneic isografting techniques, because pre-processed CAR-T cells can be mass-produced and stored without the need to extract patient cells and genetically modify them. Kassim concluded, "This treatment demonstrates the flexibility of TALEN-adjusted cells and greatly expands the potential of genetic modification to treat tumors." Waseem Qasim Throwing Fire Extinguisher,Compact Fire Extinguisher,Portable Fire Extinguisher Ball,Fire Safety Equipment DONGGUAN TENYU TECH.INC , https://www.tenyutech.com
London College University researchers successfully cured two ALL infant patients with CAR-T technology